1
Clinical Trials associated with AD-PluReceptor(MD Anderson Cancer Center)Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders
The goal of Safety Lead-In is to confirm the safety of tafasitamab when given to patients with SSc, SLE, and LN.
The goal of Phase 1 is to find the recommended dose of AD-PluReceptor-NK cells in combination with tafasitamab and lymphodepleting chemotherapy that can be given to patients with the disease.
The goal of Phase 2 is to learn if the dose of AD-PluReceptor-NK cells found in Phase 1 in combination with tafasitamab and lymphodepleting chemotherapy can help to control the disease.
100 Clinical Results associated with AD-PluReceptor(MD Anderson Cancer Center)
100 Translational Medicine associated with AD-PluReceptor(MD Anderson Cancer Center)
100 Patents (Medical) associated with AD-PluReceptor(MD Anderson Cancer Center)
100 Deals associated with AD-PluReceptor(MD Anderson Cancer Center)